73101-74-3

Usage

Uses

Used in Pharmaceutical Industry:
2-bromomethylbenzoxazole is used as a functional group in the development of pharmaceuticals for its ability to interact with other molecules, potentially contributing to the efficacy and properties of the final drug product.
Used in Chemical Synthesis:
In the field of chemical synthesis, 2-bromomethylbenzoxazole is used as a building block or intermediate for creating more complex molecules, taking advantage of its reactivity and structural features to form new compounds with desired properties.
Used in Research Applications:
2-bromomethylbenzoxazole is utilized in research settings to study the interactions between molecules and to explore its potential applications in various chemical and biological processes, furthering our understanding of its role and capabilities in scientific and industrial applications.

Upstream product

• 95-21-6 2-methyl-1,3-benzoxazole 
• 40070-39-1 triethyl orthobromoacetate 
• 95-55-6 2-amino-phenol 
• 79-08-3 bromoacetic acid 

Downstream Products

• 73101-70-9 2-sulfamoylmethylbenzoxazole 
• 73101-73-2 benzoxazolemethanesulfonyl chloride 
• 136727-12-3 2-[(Methylamino)methyl]benzoxazole 
• 1254122-51-4 C₁₉H₁₈N₂O₅ 
• 1254122-50-3 C₁₉H₁₈N₂O₅ 
• 138128-87-7 (3-Benzooxazol-2-ylmethyl-4-oxo-3,4-dihydro-phthalazin-1-yl)-acetic acid 4-methoxy-benzyl ester 
• 27628-41-7 2-benzenesulfonylmethyl-benzooxazole 

Relevant academic research and scientific papers

Multi-substituted amine compound and its preparation and use (by machine translation)

The invention belongs to the field of medical technology, in particular, the present invention provides the following formula I shown multi-substituted amine compound or its isomer or its pharmaceutically acceptable salt, ester, prodrug or hydrate, its pharmaceutical composition, preparation method thereof and its use in the preparation of medicine for treating aids in use. The compound or pharmaceutical composition containing the compound can be used as an inhibitor for inhibiting HIV integrase with LEDGF/p75 between protein - protein interaction and HIV integrase dimerization, then can be used for the treatment of aids. . (by machine translation)

Benzoxazole and dioxolane substituted benzimidazole–based N–heterocyclic carbene–silver(I) complexes: Synthesis, structural characterization and in vitro antimicrobial activity

A novel series of 1,3–benzoxazole and 1,3–dioxolane substituted benzimidazole–based N–heterocyclic carbene (NHC) precursors (6a–b and 11a–b) and their corresponding NHC–silver(I) acetate (12a–b and 14a–b) and bis–NHC–silver(I) hexafluorophosphate complexe

Oxazole light triggered protecting groups: Synthesis and photolysis of fused heteroaromatic conjugates

Fused oxazole derivatives were synthesized and evaluated as new light triggered protecting groups by using amino acids as model bifunctional molecules. The photosensitivity of ester conjugates was tested under irradiation at 254, 300, and 350 nm. Oxazole

Antimicrobial lexitropsins containing amide, amidine, and alkene linking groups

The synthesis and properties of 80 short minor groove binders related to distamycin and the thiazotropsins are described. The design of the compounds was principally predicated upon increased affinity arising from hydrophobic interactions between minor groove binders and DNA. The introduction of hydrophobic aromatic head groups, including quinolyl and benzoyl derivatives, and of alkenes as linkers led to several strongly active antibacterial compounds with MIC for Staphylococcus aureus, both methicillin-sensitive and -resistant strains, in the range of 0.1-5 μg mL-1, which is comparable to many established antibacterial agents. Antifungal activity was also found in the range of 20-50 μg mL-1 MIC against Aspergillus niger and Candida albicans, again comparable with established antifungal drugs. A quinoline derivative was found to protect mice against S. aureus infection for a period of up to six days after a single intraperitoneal dose of 40 mg kg-1.

TETRAHYDROCARBAZOLES AND DERIVATIVES

The present invention relates to compounds of the formula (I) wherein R1, R2, R3, R4, R5, X1, X2, X3, X4, n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and/or LXR? agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.

Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity

Vitronectin receptor antagonists having the formula: STR1 which are useful for the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporsis.

Aniline derivatives having herbicidal activity, their preparation and their use

Compounds of formula (I): STR1 (wherein: R1 is optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy, or optionally substituted alkylthio; R2 is hydrogen, optionally substituted alkyl, cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl or a group of formula --YR7 ; R3 is optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy group, optionally substituted alkenyl, optionally substituted alkynyl, halogen, nitro or a group of formula --COR8, wherein R8 is hydrogen, alkyl, cycloalkyl or alkoxy; R4 and R5 are each hydrogen atom or alkyl; R6 is optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy group, optionally substituted alkenyl, optionally substituted alkynyl, halogen, nitro, or a group of formula --COR8, as defined above; A, Q and X are each oxygen or sulfur; Y is a group of formula --CO--, --COO--, --CH2 O--, --CH2 S--, --CH2 CH2 O--, --CH2 CH2 S--, --CH2 CO--, --CH2 COO--, --CH(Me)COO--, --CH2 CH2 CO--, --CH2 OCO--, CH2 OCOO-- and --CH2 CH2 OCO--; R7 is optionally substituted alkyl group, cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, or an optionally substituted heterocycle; and m and n are each an integer from 0 to 4; and herbicidally acceptable addition salts thereof) are useful as herbicides.

Syntheses of 2-sulfamoylmethylbenzoxazole derivatives and determination of their anticonvulsant activities

Some 2-sulfamoylmethylbenzoxazole derivatives were synthesized from 2-bromomethylbenzoxazole by reaction with sodium bisulfite, followed by chlorination and amination. Among them, 2-sulfamoylmethylbenzoxazole showed the strongest anticonvulsant activity, which was compared with that of 3-sulfamoylmethyl-1,2-benzisoxazole (I).